Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.

Richard Greil; Alessandra Tedeschi; Carol Moreno; Bertrand Anz; Loree Larratt; Martin Simkovic; Devinder Gill; John G Gribben; Ian W Flinn; Zhengyuan Wang; Leo W K Cheung; Aaron N Nguyen; Cathy Zhou; Lori Styles; Fatih Demirkan

doi:10.1007/s00277-021-04536-6

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.

Richard Greil^* (First author), Alessandra Tedeschi, Carol Moreno, Bertrand Anz, Loree Larratt, Martin Simkovic, Devinder Gill, John G Gribben, Ian W Flinn, Zhengyuan Wang, Leo W K Cheung, Aaron N Nguyen, Cathy Zhou, Lori Styles, Fatih Demirkan

^*Corresponding author for this work

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

9 Citations (Web of Science)

Original language	English
Pages (from-to)	1733-1742
Journal	ANNALS OF HEMATOLOGY
Volume	100
Issue number	7
DOIs	https://doi.org/10.1007/s00277-021-04536-6
Publication status	Published - 2021

Keywords

CHRONIC LYMPHOCYTIC-LEUKEMIA
RELEASE SYNDROME
INITIAL THERAPY
RITUXIMAB
CELLS
BENDAMUSTINE
MONOTHERAPY

Access to Document

10.1007/s00277-021-04536-6

Cite this

Greil, R., Tedeschi, A., Moreno, C., Anz, B., Larratt, L., Simkovic, M., Gill, D., Gribben, J. G., Flinn, I. W., Wang, Z., Cheung, L. W. K., Nguyen, A. N., Zhou, C., Styles, L., & Demirkan, F. (2021). Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. ANNALS OF HEMATOLOGY , 100(7), 1733-1742. https://doi.org/10.1007/s00277-021-04536-6

Greil, Richard ; Tedeschi, Alessandra ; Moreno, Carol et al. / Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. In: ANNALS OF HEMATOLOGY 2021 ; Vol. 100, No. 7. pp. 1733-1742.

@article{0f66f896ffec4cd1a9156962b146a207,

title = "Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.",

keywords = "CHRONIC LYMPHOCYTIC-LEUKEMIA, RELEASE SYNDROME, INITIAL THERAPY, RITUXIMAB, CELLS, BENDAMUSTINE, MONOTHERAPY",

author = "Richard Greil and Alessandra Tedeschi and Carol Moreno and Bertrand Anz and Loree Larratt and Martin Simkovic and Devinder Gill and Gribben, {John G} and Flinn, {Ian W} and Zhengyuan Wang and Cheung, {Leo W K} and Nguyen, {Aaron N} and Cathy Zhou and Lori Styles and Fatih Demirkan",

note = "Greil: Paracelsus Med Univ, Salzburg Canc Res Inst CCCIT, Canc Cluster Salzburg, Med Dept 3, Salzburg, Austria; ",

year = "2021",

doi = "10.1007/s00277-021-04536-6",

language = "English",

volume = "100",

pages = "1733--1742",

journal = "ANNALS OF HEMATOLOGY ",

issn = "0939-5555",

number = "7",

}

Greil, R, Tedeschi, A, Moreno, C, Anz, B, Larratt, L, Simkovic, M, Gill, D, Gribben, JG, Flinn, IW, Wang, Z, Cheung, LWK, Nguyen, AN, Zhou, C, Styles, L & Demirkan, F 2021, 'Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.', ANNALS OF HEMATOLOGY , vol. 100, no. 7, pp. 1733-1742. https://doi.org/10.1007/s00277-021-04536-6

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. / Greil, Richard (First author); Tedeschi, Alessandra; Moreno, Carol et al.
In: ANNALS OF HEMATOLOGY , Vol. 100, No. 7, 2021, p. 1733-1742.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.

AU - Greil, Richard

AU - Tedeschi, Alessandra

AU - Moreno, Carol

AU - Anz, Bertrand

AU - Larratt, Loree

AU - Simkovic, Martin

AU - Gill, Devinder

AU - Gribben, John G

AU - Flinn, Ian W

AU - Wang, Zhengyuan

AU - Cheung, Leo W K

AU - Nguyen, Aaron N

AU - Zhou, Cathy

AU - Styles, Lori

AU - Demirkan, Fatih

N1 - Greil: Paracelsus Med Univ, Salzburg Canc Res Inst CCCIT, Canc Cluster Salzburg, Med Dept 3, Salzburg, Austria;

PY - 2021

Y1 - 2021

KW - CHRONIC LYMPHOCYTIC-LEUKEMIA

KW - RELEASE SYNDROME

KW - INITIAL THERAPY

KW - RITUXIMAB

KW - CELLS

KW - BENDAMUSTINE

KW - MONOTHERAPY

U2 - 10.1007/s00277-021-04536-6

DO - 10.1007/s00277-021-04536-6

M3 - Original Article

C2 - 34018029

SN - 0939-5555

VL - 100

SP - 1733

EP - 1742

JO - ANNALS OF HEMATOLOGY

JF - ANNALS OF HEMATOLOGY

IS - 7

ER -

Greil R, Tedeschi A, Moreno C, Anz B, Larratt L, Simkovic M et al. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. ANNALS OF HEMATOLOGY . 2021;100(7):1733-1742. doi: 10.1007/s00277-021-04536-6